Results 21 to 30 of about 81,637 (175)

One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study. [PDF]

Ophthalmol Ther
Introduction The aim of this study was to compare the efficacy of the treat-and-extend (TAE) regimen versus the pro re nata (PRN) regimen in patients with bevacizumab-resistant diabetic macular edema (DME) treated with aflibercept, with or without ...
Yozgat Z, Isik MU, Sabaner MC.
europepmc   +2 more sources

Pro Re Nata Prescription and Perception Difference between Doctors and Nurses. [PDF]

Korean J Fam Med, 2014
Pro re nata (PRN) prescription is a frequently used prescription method in hospitals. This study was conducted to investigate actual condition of PRN prescription and whether administration error occurred because of perception difference between doctors and nurses.From May to July 2012, a survey was conducted among 746 doctors and nurses (88 doctors ...
Oh SH, Woo JE, Lee DW, Choi WC, Yoon JL, Kim MY.   +5 more
europepmc   +4 more sources

Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen. [PDF]

J Ophthalmol, 2018
Purpose. To compare the qualitative and quantitative choroidal neovascularization (CNV) changes after antivascular endothelial growth factor (anti-VEGF) therapy in treatment-naïve and treated eyes with age-related macular degeneration (AMD) using optical
Miere A, Oubraham H, Amoroso F, Butori P, Astroz P, Semoun O, Bruyere E, Pedinielli A, Addou-Regnard M, Jung C, Cohen SY, Souied EH.   +11 more
europepmc   +2 more sources

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. [PDF]

BMC Ophthalmol, 2018
Background To assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD).
Elwes F, Borooah S, Aspinall P, Sim PY, Loo CY, Armbrecht AM, Dhillon B, Cackett P.   +7 more
europepmc   +2 more sources

Lost to follow-up while undergoing intravitreal injection therapy: barriers to adherence in a real-world setting. [PDF]

Int J Retina Vitreous
Background Intravitreal anti‑VEGF therapy is effective, yet real‑world outcomes are limited by non persistence. We investigated patient‑reported reasons for discontinuation under pro-re-nata therapy protocol. Methods This ambispective real-world study at
Licht A, Mavris Y, Latz C, Schuster AK, Ponto KA, Mirshahi A.   +5 more
europepmc   +2 more sources

One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial. [PDF]

J Ophthalmol, 2019
Purpose. To compare the functional and anatomical outcomes of one dose and three loading doses followed by the pro re nata (PRN) regimen in Chinese neovascular age-related macular degeneration (nvAMD) (including polypoidal choroidal vasculopathy (PCV ...
Wang F, Yuan Y, Wang L, Ye X, Zhao J, Shen M, Zhang Q, Xu D, Qin G, Zhang W, Yuan F, Chang Q, Zhao P, Wang F, Sun X.   +14 more
europepmc   +2 more sources

‘Sometimes we just have to trust our gut feeling and hope the reporting is good’.

Tidsskrift for Omsorgsforskning, 2021
Objective: Pro re nata (as needed) medications are widely used among older patients in long-term care. Current knowledge of healthcare providers’ administration of these medications and the decisions involving these medications is scarce and mainly ...
Marianne Kollerøs Nilsen, Hege Sletvold, Rose Mari Olsen   +2 more
doaj   +1 more source

A Tool to Ensure Appropriate Drug Use and Maintain Patient Safety When Administering Pro Re Nata Medications: Healthcare Providers’ Experiences With Medicine Lists in Sheltered Housing for Older People [PDF]

, 2022
Residents living in sheltered housing may need assistance with the administration of medications, including medications used as needed. Healthcare providers can then administer medications based on the resident’s medication list. The aim of this study is
Bell, Hege Therese, Nilsen, Marianne Kollerøs   +1 more
core   +1 more source

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience

Türk Oftalmoloji Dergisi, 2023
Objectives:To compare the functional and anatomical outcomes of ranibizumab and aflibercept monotherapies given according to a pro re nata (PRN) protocol in treatment-naive eyes with diabetic macular edema (DME) in a real-life clinical setting.Materials ...
Mahmut Kaya, Taylan Öztürk, Nilüfer Koçak, Betül Akbulut Yağcı, Ferdane Ataş, Süleyman Kaynak   +5 more
doaj   +1 more source

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1 [PDF]

Türk Oftalmoloji Dergisi, 2018
Objectives: To evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in neovascular age-related macular degeneration (nAMD) patients.
Abdullah Özkaya, Levent Karabaş, Cengiz Alagöz, Zeynep Alkın, Özgür Artunay, Selim Bölükbaşı, Gökhan Demir, Mehmet Demir, Ali Demircan, Burak Erden, Gürkan Erdoğan, Mehmet Erdoğan, Erdem Eriş, Havva Kaldırım, İsmail Umut Onur, Özen Osmanbaşoğlu, Sezin Özdoğan Erkul, Mine Öztürk, İrfan Perente, Kübra Sarıcı, Nihat Sayın, Dilek Yaşa, İhsan Yılmaz, Zeynep Yılmazabdurrahmanoğlu   +23 more
doaj   +1 more source